Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Pfizer-BioNTech hopes to be able to manufacture up to 1.3 billion doses in 2021 and Moderna says it is optimistic about producing 500 million to one billion doses in the next year
1 view
Skip to first unread message
Amine Moulay Ramdane
Dec 4, 2020, 11:42:22 AM12/4/20
to
Hello..
Pfizer-BioNTech hopes to be able to manufacture up to 1.3 billion doses in 2021 and Moderna says it is optimistic about producing 500 million to one billion doses in the next year.
Moderna revealed on Monday the results obtained two weeks after the administration of the second dose of his vaccine. Of the 30,000 people who took part in the clinical trial, 196 exhibited symptoms of COVID-19 and tested positive following a drug test. Of these 196 cases, 185 had received a placebo, which was given to half of the volunteers. None of the 11 cases of COVID-19 that occurred in the vaccinated group, however, suffered from the severe form of the infection, while 30 of the 185 cases in the placebo group were severely affected and one participant even succumbed to his illness. infection. These data therefore mean that the vaccine's effectiveness in preventing COVID-19 was 94.1%, and its effectiveness in limiting serious infections was 100%.The company also said the vaccine's effectiveness was found to be comparable across all ages and in all ethnic communities.
Canada's “secure” place in the vaccine access queue
Read more here:
https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=https%3A%2F%2Fwww.ledevoir.com%2Fsociete%2Fscience%2F590727%2Fla-place-du-canada-securisee-dans-la-file-d-attente-pour-l-acces-aux-vaccins
Thank you,
Amine Moulay Ramdane.
Pfizer-BioNTech hopes to be able to manufacture up to 1.3 billion doses in 2021 and Moderna says it is optimistic about producing 500 million to one billion doses in the next year.
Moderna revealed on Monday the results obtained two weeks after the administration of the second dose of his vaccine. Of the 30,000 people who took part in the clinical trial, 196 exhibited symptoms of COVID-19 and tested positive following a drug test. Of these 196 cases, 185 had received a placebo, which was given to half of the volunteers. None of the 11 cases of COVID-19 that occurred in the vaccinated group, however, suffered from the severe form of the infection, while 30 of the 185 cases in the placebo group were severely affected and one participant even succumbed to his illness. infection. These data therefore mean that the vaccine's effectiveness in preventing COVID-19 was 94.1%, and its effectiveness in limiting serious infections was 100%.The company also said the vaccine's effectiveness was found to be comparable across all ages and in all ethnic communities.
Canada's “secure” place in the vaccine access queue
Read more here:
https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=https%3A%2F%2Fwww.ledevoir.com%2Fsociete%2Fscience%2F590727%2Fla-place-du-canada-securisee-dans-la-file-d-attente-pour-l-acces-aux-vaccins
Thank you,
Amine Moulay Ramdane.
0 new messages